Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 84

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 84
---
 technologies, may seek, or may already have obtained, patents
that will limit, interfere with, or eliminate our ability to make, use, and sell our potential products either in the United States or
in international markets; there may be significant pressure on the United States government and other international governmental bodies
to limit the scope of patent protection both inside and outside the United States for treatments that prove successful as a matter of
public policy regarding worldwide health concerns; countries other than the United States may have less restrictive patent laws than those
upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing
products.

Moreover, any patents issued
to us may not provide us with meaningful protection, or others may challenge, circumvent or narrow our patents. Third parties may also
independently develop products similar to our products, duplicate our unpatented products or design around any patents on products we
develop. Additionally, extensive time is required for development, testing and regulatory review of a potential product. While extensions
of patent term due to regulatory delays may be available, it is possible that, before any of our product candidates can be commercialized,
any related patent, even with an extension, may expire or remain in force for only a short period following commercialization, thereby
reducing any advantages of the patent.

In addition, the United States
Patent and Trademark Office (the “USPTO”) and patent offices in other jurisdictions have often required that patent applications
concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations
exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Thus, even if we or our
licensors are able to obtain patents, the patents may be substantially narrower than anticipated.

49

Our success depends on patent
applications that are licensed exclusively to us and other patents to which we may obtain assignment or licenses. We may not be aware,
however, of all patents, published applications or published literature that may affect our business either by blocking our ability to
commercialize our product candidates, by preventing the patentability of our product candidates to us or our licensors, or by covering
the same or similar technologies that may invalidate our patents, limit the scope of our future patent claims or adversely affect our
ability to market our product candidates.

In addition to patents, we
rely on a combination of trade secrets, confidentiality, nondisclosure and other contractual provisions